ACR: First-Line Rituximab May Improve Survival in RA-ILD

This article originally appeared here.
Share this content:
ACR: First-Line Rituximab May Improve Survival in RA-ILD
ACR: First-Line Rituximab May Improve Survival in RA-ILD

MONDAY, Nov. 14, 2016 (HealthDay News) -- For patients with rheumatoid arthritis (RA) with interstitial lung disease (ILD), long-term survival seems better for those who receive rituximab as their first biologic rather than a tumor necrosis factor-α inhibitor (TNFi), according to a study presented at the annual meeting of the American College of Rheumatology, held from Nov. 12 to 16 in Washington, D.C.

Katie Druce, Ph.D., from the Arthritis U.K. Centre for Epidemiology at the University of Manchester, and colleagues examined five-year mortality in patients with RA-ILD starting either rituximab or TNFi as their first biologic therapy for RA.

The researchers found that there were 76 deaths in 804.9 person-years in the TNFi cohort and eight deaths in 156.7 person-years in the rituximab cohort during five years of follow-up. Per 1,000 person-years, the deaths rates were 94.4 and 51.0 in the TNFi and rituximab cohorts, respectively. In 36.5 percent of the 74 available death certificates from the TNFi cohort and all three certificates in the rituximab cohort, ILD was recorded. In the rituximab treated patients, the unadjusted mortality risk was numerically half that seen in the TNFi-treated patients, although the difference was not statistically significant (hazard ratio, 0.51; 95 percent confidence interval, 0.25 to 1.06).

"The main message is that the death rates among patients with RA-ILD who started rituximab as their first biologic were lower compared to patients who started a TNFi," a coauthor said in a statement.

One author disclosed financial ties to AbbVie and Pfizer.

Abstract
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

More U.S. Teens Are Vaping, but Use of Opioids, Alcohol Falling

More U.S. Teens Are Vaping, but Use of ...

About 37 percent of 12th graders said they had vaped within the previous 12 months

Type 2 Diabetes Risk Lower in Women With Active Migraine

Type 2 Diabetes Risk Lower in Women With ...

Prevalence of active migraine decreased linearly in the 24 years prior to diabetes diagnosis

Buprenorphine-Naloxone Cost-Effective for Opioid Use Disorder

Buprenorphine-Naloxone Cost-Effective for Opioid Use Disorder

Treatment costs less than extended-release naltrexone without negative impact on outcomes

is free, fast, and customized just for you!




Already a member?

Sign In Now »